Results 1 to 10 of about 1,753 (162)

Lebrikizumab in the personalized management of asthma [PDF]

Biologics: Targets and Therapy, 2012
Neil C Thomson,1 Manish Patel,2 Andrew D Smith21Institute of Infection, Immunity, and Inflammation, University of Glasgow and Respiratory Medicine, Gartnavel General Hospital, Glasgow, UK; 2Department of Respiratory Medicine, Wishaw Hospital, Wishaw ...
Neil C Thomson
exaly   +12 more sources

Budget Impact Analysis of Lebrikizumab for Treating Severe Atopic Dermatitis [PDF]

Dermatology and Therapy
Introduction Lebrikizumab is a novel monoclonal antibody that targets interleukin-13, a pivotal factor in atopic dermatitis (AD). Previous studies revealed a positive benefit–risk profile of lebrikizumab as treatment for patients with moderate-to-severe ...
Ippazio Cosimo Antonazzo, Giampiero Girolomoni, Cataldo Patruno, Roberto Langella, Veronica Ottobrino, Lorenzo Giovanni Mantovani, Paolo Angelo Cortesi   +6 more
doaj   +9 more sources

Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin) [PDF]

Dermatology and Therapy
Introduction The efficacy and safety of lebrikizumab, a high-affinity monoclonal antibody targeting interleukin-13, were investigated in patients with moderate-to-severe atopic dermatitis (AD) up to 52 weeks in phase 3 trials.
Diamant Thaçi, Emma Guttman-Yassky
exaly   +4 more sources

Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS)

Clinical and Translational Allergy, 2022
Background Lebrikizumab is a monoclonal antibody that modulates activity of interleukin‐13. The Phase 3 ACOUSTICS study assessed lebrikizumab efficacy and safety in adolescents with uncontrolled asthma despite standard‐of‐care treatment.
Graham Roberts, Piotr Kuna
exaly   +3 more sources

Managing Atopic Dermatitis with Lebrikizumab – The Evidence to Date

Clinical, Cosmetic and Investigational Dermatology, 2022
Atopic dermatitis is a prevalent, inflammatory skin disease that presents with an eczematous, itchy rash. As of late, there have been many emerging monoclonal antibody inhibitor and small molecule therapies that have changed the course of eczema treatment. One of the treatments in the pipeline for atopic dermatitis is interleukin 13 monoclonal antibody
TERESA Ju, Angelina Labib
exaly   +5 more sources

Real-world Effectiveness and Safety of Lebrikizumab in Atopic Dermatitis: A TREATgermany Analysis [PDF]

Acta Dermato-Venereologica
Atopic dermatitis (AD) is driven by type 2 inflammation, with interleukin-13 (IL-13) as one of the central operators. Lebrikizumab is a monoclonal antibody that inhibits IL-13 signalling.
Barbara Kind, Christina Pham, Luise Heinrich, Tatjana Honstein, Annice Heratizadeh, Inken Harder, Dora Stölzl, Petra Staubach-Renz, Thomas Schaefer, Susanne Abraham, Matthias Augustin, Jutta Ramaker-Brunke, Andreas Pinter, Kathrin Meinhardt, Sven Quist, Sabine Anders, Beate Schwarz, Michael Schulz-Kiesow, Sabine Steinke, Nicole Adler, Christiane Handrick, Knut Schaekel, Michael Sticherling, Anne Bong, Felix D. Jacobs, Bernd Großmann, Maren Stahl, Carl-Philipp Buerkle, Hannah L. Gorriahn-Maiterth, Tilo Biedermann, Jochen Schmitt, Stephan Weidinger, Thomas Werfel   +32 more
doaj   +3 more sources

Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab

Dermatology and Therapy, 2023
Introduction IL-13 is the primary upregulated cytokine in atopic dermatitis (AD) skin and is the pathogenic mediator driving AD pathophysiology. Lebrikizumab, tralokinumab and cendakimab are therapeutic monoclonal antibodies (mAb) that target IL-13 ...
Robert Benschop, Angela Okragly, Chetan N Patel   +2 more
exaly   +4 more sources

Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison [PDF]

Dermatology and Therapy
Introduction Dupilumab and lebrikizumab have demonstrated efficacy in atopic dermatitis (AD) clinical trials; however, no direct comparisons exist. Methods Efficacy outcome achievement (dupilumab and lebrikizumab with topical corticosteroids [TCS]) at 16 
Mike Bastian, Andreas Pintér, Sonja Stander   +2 more
exaly   +3 more sources

Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin) [PDF]

Dermatology and Therapy
Introduction We report efficacy and safety of lebrikizumab up to 152 weeks (W) of continuous treatment with/without topical corticosteroids in the ADjoin long-term extension study. Methods ADvocate1&2 W16 lebrikizumab responders (Eczema Area and Severity
Emma Guttman-Yassky, Alan D. Irvine, Melinda Gooderham, Stephan Weidinger, Lynda Spelman, Jonathan I. Silverberg, Heidi Crane, Hany ElMaraghy, Louise DeLuca-Carter, Maria Lucia Buziqui Piruzeli, Georgia Martimianaki, Evangeline Pierce, Helena Agell, Diamant Thaçi   +13 more
doaj   +2 more sources

Use of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis in Challenging Clinical Scenarios Including Atypical Presentations, Comorbidities, and Tattooed Skin Involvement: Four Case Reports [PDF]

Case Reports in Dermatology
Introduction: Lebrikizumab is a high-affinity IgG4 monoclonal antibody that selectively binds soluble interleukin (IL)-13, approved for the treatment of moderate-to-severe atopic dermatitis (AD).
Mariateresa Rossi, Natale Schettini, Eugenia Veronica Di Brizzi, Luigi Gargiulo, Anna Balato   +4 more
doaj   +2 more sources